<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">problendo</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы Эндокринологии</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0375-9660</issn><issn pub-type="epub">2308-1430</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/probl12108</article-id><article-id custom-type="elpub" pub-id-type="custom">problendo-12108</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клиническая эндокринология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical endocrinology</subject></subj-group></article-categories><title-group><article-title>Частота формирования мотивированного отказа от использования андрогенных анаболических стероидов среди мужчин, занимающихся рекреационной активностью</article-title><trans-title-group xml:lang="en"><trans-title>The frequency of formation of a motivated refusal to take androgenic anabolic steroids by men with recreational activity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6460-5226</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лихоносов</surname><given-names>Николай Павлович</given-names></name><name name-style="western" xml:lang="en"><surname>Lykhonosov</surname><given-names>Mykola P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Очный аспирант кафедры терапии факультетской с курсом эндокринологии, кардиологии и функциональной диагностики имени Г.Ф. Ланга с клиникой</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">likhonosov.np@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0559-697X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабенко</surname><given-names>Алина Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Babenko</surname><given-names>Alina Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., доцент</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">alina_babenko@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1710-8045</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макарьин</surname><given-names>Виктор Алексеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Makarin</surname><given-names>Viktor A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.мед.н </p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">mvaviktor@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0445-9428</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федотов</surname><given-names>Юрий Николаевич</given-names></name><name name-style="western" xml:lang="en"><surname>Fedotov</surname><given-names>Yury  N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">6762525@gosmed.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова; Санкт-Петербургский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University; Saint-Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова; Национальный медицинский исследовательский центр им. В.А. Алмазова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University; Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>11</month><year>2019</year></pub-date><volume>65</volume><issue>5</issue><fpage>341</fpage><lpage>350</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лихоносов Н.П., Бабенко А.Ю., Макарьин В.А., Федотов Ю.Н., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Лихоносов Н.П., Бабенко А.Ю., Макарьин В.А., Федотов Ю.Н.</copyright-holder><copyright-holder xml:lang="en">Lykhonosov M.P., Babenko A.Y., Makarin V.A., Fedotov Y.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.probl-endojournals.ru/jour/article/view/12108">https://www.probl-endojournals.ru/jour/article/view/12108</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Широкое использование андрогенных анаболических стероидов (ААС) в немедицинских целях все чаще становится причиной вторичного гипогонадизма, в связи с чем большую актуальность представляет разработка методов формирования отрицательного отношения к использованию ААС среди посетителей тренажерных залов.</p></sec><sec><title>Цель</title><p>Цель: определить частоту формирования мотивированного отказа от дальнейшего использования андрогенных анаболических стероидов среди мужчин, добровольно заявивших об их использовании.</p></sec><sec><title>Методы</title><p>Методы. В исследование включены 44 мужчины, употребляющих ААС. Оценивали результативность клинического обследования: степень готовности к раскрытию информации о применении ААС (препараты, дозы, схемы, длительность), уровень информированности о механизмах действия ААС, их влияние на организм, предлагали оценить психоэмоциональный фон (шкалы «Индекса жизненной удовлетворенности», депрессии Гамильтона, агрессивности). Опыт проведенных нами информационных лекций на тему «Риски использования ААС», предшествовавших отбору добровольцев для исследования, анонимного анкетирования, собеседования с потенциальными участниками клинического исследования, самой клинической работы с отобранными добровольцами, выявленные нами особенности сбора анамнеза и обследования были сопоставлены с клиническими рекомендациями по диагностике гипогонадизма (отечественными и зарубежными).</p></sec><sec><title>Результаты</title><p>Результаты. На мотивированное (бесплатные врачебные консультации и лабораторное обследование) предложение участвовать в клиническом исследовании откликнулись 105 посетителей спортивных залов. По итогам индивидуального собеседования информированное согласие подписали 54 (51,4%) мужчины, указавшие на использование ААС. Все этапы исследования прошли 44 (41,9%) добровольца. Среди них информированы о механизмах действия и побочных эффектах ААС 72,7% (n=32). Шкалы заполнил 21 (47,7%) доброволец. Индекс шкалы жизненной удовлетворенности определялся как высокий, медиана 34 [29; 38] балла, индекс агрессивности был выше общепринятой нормы и составил 27 [25; 29] баллов, а индекс шкалы депрессии соответствовал легкому депрессивному расстройству, медиана 9 [3; 12] баллов. На фоне использования ААС 22,7% (n=10) обследованных отметили повышение агрессивности, которое сами связывают с использованием стероидов. На появление клинических симптомов гипогонадизма (снижение либидо, нарушение эрекции) после отмены ААС указали 25% (n=11) добровольцев, что послужило одной из причин продолжения использования анаболиков. Готовы отказаться полностью от применения стероидов 31,8% (n=14) участников исследования.</p></sec><sec><title>Заключение</title><p>Заключение. Индивидуальные информационные собеседования, направленные на предоставление знаний о негативном воздействии стероидов на организм, мотивировали желание отказаться от их использования у 31,8% пользователей ААС. Полученные данные указывают на сформировавшуюся зависимость от ААС, в преодолении которой необходимо участие врачей-психиатров.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: The widespread use of AAS for non-medical purposes is more than often becoming the cause of secondary hypogonadism. The study of the formation of the negative attitude towards the use of AAS among the gym visitors is quite relevant.</p></sec><sec><title>AIMS</title><p>AIMS: To identify the frequency of the formation of a motivated refusal to continue taking androgenic anabolic steroids among men who voluntarily declared their use.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: The study included 44 men, all users of AAS. There has been estimated the effectiveness of the clinical examination: how ready they were to disclose information about the use of AAS (drugs, doses, regimens, duration) or how much they were aware of the mechanisms of action of AAS and their effects on the body. The participants were also asked to evaluate their psychological and emotional state (on the scale “Index of life satisfaction”, Hamilton’s depression, aggressiveness). The experience of our informational lectures on the topic “Risks of using AAS” prior to the selection of volunteers for research, anonymous surveys and interviews with potential participants in the clinical trial, the clinical work itself with the selected volunteers, the characteristic features of a medical history and tests that we identified were compared with clinical recommendations for hypogonadism diagnostic (domestic and foreign).</p></sec><sec><title>RESULTS</title><p>RESULTS: More than 105 gym visitors responded positively to a motivated offer (free medical consultation and laboratory tests) to participate in a clinical study. Based on the results of the individual interview, 54 men (51.4%) who indicated the use of AAS signed an informed consent. 44 volunteers (41.9%) completed all stages of the study. Among them, 32 participants (72.7%) were aware of the mechanisms of action and side effects of AAS. 21 volunteers (47.7%) filled in the scales. The index of life satisfaction was determined as high, equal to 34 [29; 38] points; the index of aggressiveness was higher than the generally accepted standard and composed 27 [25; 29] points, the level of depression corresponded to a mild depressive disorder, equal to 9 [3; 12] points. Over the use of AAS 22.7% (n = 10) of the examined noted an increase in aggressiveness, which they themselves associated with the use of steroids. The clinical symptoms of hypogonadism (decreased libido, erectile dysfunction) after the cancellation of AAS were indicated by 25% (n = 11) of the volunteers and that was one of the reasons they continued to use anabolics. 31.8% (n = 14) of the participants were ready to completely stop using the steroids.</p></sec><sec><title>CONCLUSIONS</title><p>CONCLUSIONS: Individual informational interviews aimed at providing knowledge about the negative effects of steroids on the body motivated the desire to stop using them amongst 31.8% of AAS users. The obtained data points out to a developed AAS addiction which requires the involvement of psychiatrists to get rid of it.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>анаболические андрогенные стероиды</kwd><kwd>злоупотребление стероидами</kwd><kwd>поведенческие особенности</kwd><kwd>гипогонадизм</kwd></kwd-group><kwd-group xml:lang="en"><kwd>anabolic-androgenic steroids</kwd><kwd>Abuse of steroids</kwd><kwd>behavioral features</kwd><kwd>hypogonadism</kwd><kwd>Steroid-induced hypogonadism</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке Клиники высоких медицинских технологий им. Н.И. Пирогова Санкт-Петербургского государственного университета.</funding-statement><funding-statement xml:lang="en">The study was carried out with the financial support of the High Medical Technology Clinic named after N.I. Pyrogov of St. Petersburg State University.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Levine H, Jørgensen N, Martino-Andrade A, et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update. 2017;23(6):646-659. doi: https://doi.org/10.1093/humupd/dmx022</mixed-citation><mixed-citation xml:lang="en">Levine H, Jørgensen N, Martino-Andrade A, et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update. 2017;23(6):646-659. doi: https://doi.org/10.1093/humupd/dmx022</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Travison TG, Araujo AB, O’Donnell AB, et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196-202. doi: https://doi.org/10.1210/jc.2006-1375</mixed-citation><mixed-citation xml:lang="en">Travison TG, Araujo AB, O’Donnell AB, et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196-202. doi: https://doi.org/10.1210/jc.2006-1375</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990;18(4):429-431. doi: https://doi.org/10.1177/036354659001800417</mixed-citation><mixed-citation xml:lang="en">Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990;18(4):429-431. doi: https://doi.org/10.1177/036354659001800417</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Coward RM, Rajanahally S, Kovac JR, et al. Anabolic steroid induced hypogonadism in young men. J Urol. 2013;190(6):2200-2205. doi: https://doi.org/10.1016/j.juro.2013.06.010</mixed-citation><mixed-citation xml:lang="en">Coward RM, Rajanahally S, Kovac JR, et al. Anabolic steroid induced hypogonadism in young men. J Urol. 2013;190(6):2200-2205. doi: https://doi.org/10.1016/j.juro.2013.06.010</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sagoe D. Methods used in a meta-analysis and meta-regression analysis of the global epidemiology of anabolic-androgenic steroid use. Publishing Company: SAGE Publications, Ltd; 2014. doi: https://doi.org/10.4135/978144627305014537438</mixed-citation><mixed-citation xml:lang="en">Sagoe D. Methods used in a meta-analysis and meta-regression analysis of the global epidemiology of anabolic-androgenic steroid use. Publishing Company: SAGE Publications, Ltd; 2014. doi: https://doi.org/10.4135/978144627305014537438</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lykhonosov MP, Babenko AYu. The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint-Petersburg. Problemy endokrinologii. 2019;65(1):19-30. doi: 10.14341/probl9832</mixed-citation><mixed-citation xml:lang="en">Lykhonosov MP, Babenko AYu. The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint-Petersburg. Problemy endokrinologii. 2019;65(1):19-30. doi: 10.14341/probl9832</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users’ attitudes towards physicians. Addiction. 2004;99(9): 1189−1194. doi: https://doi.org/10.1111/j.1360-0443.2004.00781.x</mixed-citation><mixed-citation xml:lang="en">Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users’ attitudes towards physicians. Addiction. 2004;99(9): 1189−1194. doi: https://doi.org/10.1111/j.1360-0443.2004.00781.x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pope HG, Kanayama G. Treatment of anabolic-androgenic steroid related disorders. Textbook of addiction treatment: International perspectives. Springer Link. 2014. рр. 621-636. doi: https://doi.org/10.1007/978-88-470-5322-9_28</mixed-citation><mixed-citation xml:lang="en">Pope HG, Kanayama G. Treatment of anabolic-androgenic steroid related disorders. Textbook of addiction treatment: International perspectives. Springer Link. 2014. рр. 621-636. doi: https://doi.org/10.1007/978-88-470-5322-9_28</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Order № 780n Ministry Of Health Russia «Ob utverzhdenii standarta pervichnoy mediko-sanitarnoi pomoshchi pri gipogonadizme», dated 2012 Nov 9. https://base.garant.ru/70304310/.</mixed-citation><mixed-citation xml:lang="en">Order № 780n Ministry Of Health Russia «Ob utverzhdenii standarta pervichnoy mediko-sanitarnoi pomoshchi pri gipogonadizme», dated 2012 Nov 9. https://base.garant.ru/70304310/.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Karelin A. Bol’shaia entsiklopediia psikhologicheskikh testov. Moscow: Exmo; 2007. 416 р.</mixed-citation><mixed-citation xml:lang="en">Karelin A. Bol’shaia entsiklopediia psikhologicheskikh testov. Moscow: Exmo; 2007. 416 р.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dermanova IB. Diagnostika emotsional’no-nravstvennogo razvitiia. St. Petersburg: Rech’; 2002. 171 р.</mixed-citation><mixed-citation xml:lang="en">Dermanova IB. Diagnostika emotsional’no-nravstvennogo razvitiia. St. Petersburg: Rech’; 2002. 171 р.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56−62. doi: https://doi.org/10.1136/jnnp.23.1.56</mixed-citation><mixed-citation xml:lang="en">Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56−62. doi: https://doi.org/10.1136/jnnp.23.1.56</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bland M. An introduction to medical statistics (Oxford Medical Publications). 3rd ed. Oxford University Press, Oxford; 2000. рр. 335-347.</mixed-citation><mixed-citation xml:lang="en">Bland M. An introduction to medical statistics (Oxford Medical Publications). 3rd ed. Oxford University Press, Oxford; 2000. рр. 335-347.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McBride JA, Carson CC, Coward RM. The availability and acquisition of illicit anabolic androgenic steroids and testosterone preparations on the Internet. Am J Mens Health. 2018;12(5):1352-1357. doi: https://doi.org/10.1177/1557988316648704</mixed-citation><mixed-citation xml:lang="en">McBride JA, Carson CC, Coward RM. The availability and acquisition of illicit anabolic androgenic steroids and testosterone preparations on the Internet. Am J Mens Health. 2018;12(5):1352-1357. doi: https://doi.org/10.1177/1557988316648704</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kanayama G, Brower KJ, Wood RI, et al. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12): 1966-1978. doi: https://doi.org/10.1111/j.1360-0443.2009.02734.x</mixed-citation><mixed-citation xml:lang="en">Kanayama G, Brower KJ, Wood RI, et al. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12): 1966-1978. doi: https://doi.org/10.1111/j.1360-0443.2009.02734.x</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Beutel A, Bergamaschi CT, Campos RR. Effects of chronic anabolic steroid treatment on tonic and reflex cardiovascular control in male rats. J Steroid Biochem Mol Biol. 2005;93(1):43-48. doi: https://doi.org/10.1016/j.jsbmb.2004.11.003</mixed-citation><mixed-citation xml:lang="en">Beutel A, Bergamaschi CT, Campos RR. Effects of chronic anabolic steroid treatment on tonic and reflex cardiovascular control in male rats. J Steroid Biochem Mol Biol. 2005;93(1):43-48. doi: https://doi.org/10.1016/j.jsbmb.2004.11.003</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Brower KJ. Anabolic steroid abuse and dependence in clinical practice. Phys Sportsmed. 2009;37(4):131-140. doi: https://doi.org/10.3810/psm.2009.12.1751.</mixed-citation><mixed-citation xml:lang="en">Brower KJ. Anabolic steroid abuse and dependence in clinical practice. Phys Sportsmed. 2009;37(4):131-140. doi: https://doi.org/10.3810/psm.2009.12.1751.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dodge T, Hoagland MF. The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend. 2011;114(2−3):100-109. doi: https://doi.org/10.1016/j.drugalcdep.2010.11.011.</mixed-citation><mixed-citation xml:lang="en">Dodge T, Hoagland MF. The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend. 2011;114(2−3):100-109. doi: https://doi.org/10.1016/j.drugalcdep.2010.11.011.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wood RI. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol. 2008;29(4):490-506. doi: https://doi.org/10.1016/j.yfrne.2007.12.002</mixed-citation><mixed-citation xml:lang="en">Wood RI. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol. 2008;29(4):490-506. doi: https://doi.org/10.1016/j.yfrne.2007.12.002</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nyberg F, Hallberg M. Interactions between opioids and anabolic androgenic steroids: implications for the development of addictive behavior. Int Rev Neurobiol. 2012;102:189-206. doi: https://doi.org/10.1016/B978-0-12-386986-9.00008-9</mixed-citation><mixed-citation xml:lang="en">Nyberg F, Hallberg M. Interactions between opioids and anabolic androgenic steroids: implications for the development of addictive behavior. Int Rev Neurobiol. 2012;102:189-206. doi: https://doi.org/10.1016/B978-0-12-386986-9.00008-9</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gårevik N, Rane A. Dual use of anabolic-androgenic steroids and narcotics in Sweden. Drug Alcohol Depend. 2010;109(1−3):144-146. doi: https://doi.org/10.1016/j.drugalcdep.2009.12.024</mixed-citation><mixed-citation xml:lang="en">Gårevik N, Rane A. Dual use of anabolic-androgenic steroids and narcotics in Sweden. Drug Alcohol Depend. 2010;109(1−3):144-146. doi: https://doi.org/10.1016/j.drugalcdep.2009.12.024</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Skarberg K, Nyberg F, Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur Addict Res. 2009;15(2):99-106. doi: https://doi.org/10.1159/000199045</mixed-citation><mixed-citation xml:lang="en">Skarberg K, Nyberg F, Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur Addict Res. 2009;15(2):99-106. doi: https://doi.org/10.1159/000199045</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kanayama G, Brower KJ, Wood RI, et al. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642-645. doi: https://doi.org/10.1176/appi.ajp.2009.08111699</mixed-citation><mixed-citation xml:lang="en">Kanayama G, Brower KJ, Wood RI, et al. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642-645. doi: https://doi.org/10.1176/appi.ajp.2009.08111699</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Park HJ. Anabolic steroid-induced hypogonadism: a challenge for clinicians. J Exerc Rehabil. 2018;14(1):2-3. doi: https://doi.org/10.12965/jer.1836036.018</mixed-citation><mixed-citation xml:lang="en">Park HJ. Anabolic steroid-induced hypogonadism: a challenge for clinicians. J Exerc Rehabil. 2018;14(1):2-3. doi: https://doi.org/10.12965/jer.1836036.018</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hildebrandt T, Lai JK, Langenbucher JW, et al. The diagnostic dilemma of pathological appearance and performance enhancing drug use. Drug Alcohol Depend. 2011;114(1):1-11. doi: https://doi.org/10.1016/j.drugalcdep.2010.09.018</mixed-citation><mixed-citation xml:lang="en">Hildebrandt T, Lai JK, Langenbucher JW, et al. The diagnostic dilemma of pathological appearance and performance enhancing drug use. Drug Alcohol Depend. 2011;114(1):1-11. doi: https://doi.org/10.1016/j.drugalcdep.2010.09.018</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kouri EM, Pope HG, Katz DL, Oliva P. Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clin J Sport Med. 1995;5(4):223-228. doi: https://doi.org/10.1097/00042752-199510000-00003</mixed-citation><mixed-citation xml:lang="en">Kouri EM, Pope HG, Katz DL, Oliva P. Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clin J Sport Med. 1995;5(4):223-228. doi: https://doi.org/10.1097/00042752-199510000-00003</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol. 2015;173(2):R47−58. doi: https://doi.org/10.1530/EJE-15-0080</mixed-citation><mixed-citation xml:lang="en">Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol. 2015;173(2):R47−58. doi: https://doi.org/10.1530/EJE-15-0080</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">De Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011;108(11):1860-1865. doi: https://doi.org/10.1111/j.1464-410X.2011.10131.x</mixed-citation><mixed-citation xml:lang="en">De Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011;108(11):1860-1865. doi: https://doi.org/10.1111/j.1464-410X.2011.10131.x</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27(9):1252-1262. doi: https://doi.org/10.1249/00005768-199509000-00004</mixed-citation><mixed-citation xml:lang="en">Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27(9):1252-1262. doi: https://doi.org/10.1249/00005768-199509000-00004</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lane HA, Grace F, Smith JC, et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest. 2006;36(7):483-488. doi: https://doi.org/10.1111/j.1365-2362.2006.01667.x</mixed-citation><mixed-citation xml:lang="en">Lane HA, Grace F, Smith JC, et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest. 2006;36(7):483-488. doi: https://doi.org/10.1111/j.1365-2362.2006.01667.x</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Olivardia R, Pope HG, Hudson JI. Muscle dysmorphia in male weightlifters: a case-control study. Am J Psychiatry. 2000;157(8): 1291-1296. doi: https://doi.org/10.1176/appi.ajp.157.8.1291</mixed-citation><mixed-citation xml:lang="en">Olivardia R, Pope HG, Hudson JI. Muscle dysmorphia in male weightlifters: a case-control study. Am J Psychiatry. 2000;157(8): 1291-1296. doi: https://doi.org/10.1176/appi.ajp.157.8.1291</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cole JC, Smith R, Halford JC, Wagstaff GF. A preliminary investigation into the relationship between anabolic-androgenic steroid use and the symptoms of reverse anorexia in both current and ex-users. Psychopharmacology (Berl). 2003;166(4):424-429. doi: https://doi.org/10.1007/s00213-002-1352-3</mixed-citation><mixed-citation xml:lang="en">Cole JC, Smith R, Halford JC, Wagstaff GF. A preliminary investigation into the relationship between anabolic-androgenic steroid use and the symptoms of reverse anorexia in both current and ex-users. Psychopharmacology (Berl). 2003;166(4):424-429. doi: https://doi.org/10.1007/s00213-002-1352-3</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Pope HG, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry. 2000;57(2):133-140; discussion 155-156. doi: https://doi.org/10.1001/archpsyc.57.2.133</mixed-citation><mixed-citation xml:lang="en">Pope HG, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry. 2000;57(2):133-140; discussion 155-156. doi: https://doi.org/10.1001/archpsyc.57.2.133</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
